CYLD and HER3 Regulate Platinum Resistance in Ovarian Cancer via Drug Efflux Pump ABCB1

Ye Zhang,Xiao-Yu Jia,Wei Wang,Jian-Ge Qiu,Wen-Jing Liu,Chen Ding,Lin Wang,Bing-Hua Jiang

DOI: https://doi.org/10.21203/rs.3.rs-1330339/v1

2022-01-01

Abstract:Abstract Background: Ovarian cancer (OC) is the most pathogenic gynecological malignant tumor in the world. Due to the difficulty of early diagnosis, most of patients developed chemo-resistance and recurrence during and after the chemotherapy. Methods: CCK8 and flow cytometry analysis were used to analyze the drug sensitivity and apoptosis effect in drug resistant and their parental cell lines (A2780, A2780-DDP, OVCAR3, OVCAR3-DDP). Cells with CYLD knockdown or overexpression were used to test its role in DDP resistance. Patient tumor samples were used to study the clinical significance of CYLD and its related molecules. Flow cytometry analysis were used to test the drug efflux effects in CYLD knockdown cells. The drug combination method were used to investigate the drug synergistic effect of cisplatin combination with ABCB1 inhibitor or HER3 inhibitor. The protein and RNA levels were determined by Western blot analysis, PCR and immunoprecipitation. The in vivo experiments were used to verify the role of CYLD in drug resistance of ovarian cancer and tumor growth.Results: we found levels of CYLD were markedly lower in ovarian DDP-resistant cancer cell lines than those of parental cell lines. CYLD knockdown in the parental cells alone was sufficient to induce DDP resistance through inhibiting cell apoptosis and promoting the drug efflux via inducing the expression of ABCB1. HER3 expression levels were much higher in the resistant cells, and HER3 was upstream mediator of CYLD suppression in the cells through STAT3 signaling. Moreover, overexpression of CYLD in the resistant cells alone was sufficient to reverse the resistant cells to become sensible to platinum-based treatment both in vitro and in vivo. Similar result showed that ABCB1 was functional downstream target of CYLD to regulate tumor growth and drug resistance both in vitro and in vivo.Conclusions: In this study, the results demonstrated that CYLD suppression and higher HER3 expression caused cisplatin resistance and poor prognosis by inhibiting cell apoptosis and promoting the drug efflux in OC. Our findings showed that HER3/CYLD/ABCB1 is a new signaling pathway to regulate tumor growth and DDP resistance, which is potential new therapeutic target to overcome DDP resistance.